Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Currently Reading
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data

With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.


With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.

Transcript

With the increased prevalence of real-world data in recent years, do you see a future where real-world data will replace clinical trials? Or will it be complementary to clinical trials and help fill in data gaps? 

  


I think the short answer is complementary. I think it’s hard to imagine how a new agent, except for the situation where the tumor is uncommon, but for a general situation where the tumor is a common tumor and you’re trying to develop a new treatment, doing a randomized prospective trial, I think will still be the gold standard. Albeit, after that approval the opportunity to expand application, to find new patients that might have benefit—because one of the criticisms of randomized trials is that they’re very selective, very restrictive. In the real world, it’s just that. There are all kinds of patients with all types of comorbidities. Their blood count may not be the same, their chemistries, etc.

And there’s an opportunity to take a new agent and see how patients outside that clinical trial would do. And we actually did this in a situation with metastatic breast cancer where we took results from a clinical trial—it was a successful trial. We took that treatment that was successful and looked at our real-world data and the good news was that it wasn’t as restrictive as the clinical trial. We found similar benefits, so this was a confirmation. There were situations where the doctor will be asked by a patient, “Oh, it worked on a clinical trial, does it work in others?” And there is now the opportunity to say yes it worked in other people, not just patients on the clinical trial. 

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up